TARGETING THE ACTIVIN TYPE II RECEPTOR PATHWAY FOR HEART FAILURE THERAPY

TARGETING THE ACTIVIN TYPE II RECEPTOR PATHWAY FOR HEART FAILURE THERAPY

Methods Targeted proteomic analyses of plasma samples from the Framingham Heart Study (n=899) and older adults with severe aortic stenosis (n=50) revealed chronic systemic activation of the catabolic Activin type II receptor (ActRII) pathway in aging and HF. [...]pharmacological or genetic blockade...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A2663-A2663
Hauptverfasser: Roh, Jason D., Quintero, Pablo, Chaudhari, Vinita, Hobson, Ryan, Yeri, Ashish, Benson, Mark, Xiao, Chungyang, Houstis, Nicholas, Platt, Colin, Bezzerides, Vassilios, Lindman, Brian R., Elmariah, Sammy, Gerszten, Robert, Lach-Trifilieff, Estelle, Glass, David, Rosenzweig, Anthony
Format: Artikel
Sprache:eng
Schlagworte:
Activin
Aging
Aortic stenosis
Cardiology
Heart diseases
Heart failure
Ligands
Older people
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods Targeted proteomic analyses of plasma samples from the Framingham Heart Study (n=899) and older adults with severe aortic stenosis (n=50) revealed chronic systemic activation of the catabolic Activin type II receptor (ActRII) pathway in aging and HF. [...]pharmacological or genetic blockade of the ActRII pathway restored cardiac function in murine models of HF due to aging, sarcomeric mutation (MHC F764L), or pressure-overload.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)33204-2